Form 4: Alnylam Pharmaceuticals Executive Sells Shares

Alnylam Pharmaceuticals reports a Form 4 filing detailing stock transactions by Chief Human Resources Officer Melissa McLaughlin.

Summary

• Melissa McLaughlin, Chief Human Resources Officer at Alnylam Pharmaceuticals, Inc. (ALNY), engaged in several stock transactions on April 2nd and April 6th, 2026.
• These transactions involved the sale of common stock, primarily to cover tax withholding obligations upon the vesting and settlement of restricted stock units.
• The sales occurred at various weighted average prices, ranging from $316.04 to $334.31 per share.
• A portion of the transactions on April 6th were executed under a Rule 10b5-1(c) trading plan adopted on December 16, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the reported stock sales are primarily for tax withholding purposes and executed under a pre-established trading plan, which are standard procedures for executives.

Positives

• The transactions were conducted under a mandatory sell-to-cover provision to satisfy tax withholding obligations, indicating compliance with financial responsibilities.
• The use of a Rule 10b5-1(c) trading plan suggests pre-planned and systematic stock management, which can be viewed positively by investors as it reduces concerns about insider trading based on material non-public information.

Negatives

• A significant number of shares were sold by a key executive, which could be perceived negatively by the market, even if for tax purposes.
• The total value of shares sold represents a reduction in the executive's direct beneficial ownership of the company's stock.

Risks

• Potential for negative market perception due to the sale of shares by a senior executive, even if for tax withholding purposes.
• The Rule 10b5-1(c) plan, while designed to mitigate insider trading concerns, still involves the disposition of company stock.

Future Outlook

This filing pertains to past transactions and does not contain forward-looking statements or guidance regarding the company's future financial performance.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine for publicly traded companies and are used to report changes in beneficial ownership by insiders. Such filings are closely watched by investors for insights into executive confidence and potential stock price movements, though sales for tax withholding are a common and expected occurrence.

Stakeholder Impact

• Shareholders: May observe a slight decrease in insider ownership, but the context of tax withholding and a 10b5-1 plan mitigates significant concern.
• Employees: The transaction relates to executive compensation and tax obligations, with no direct impact on general employee compensation or benefits.
• Creditors: No direct impact on the company's financial obligations or creditworthiness.
• Suppliers/Customers: No direct impact on business operations or relationships.

Key Dates

Keywords

Form 4, SEC Filing, Alnylam Pharmaceuticals, ALNY, Stock Sale, Insider Transaction, Melissa McLaughlin, Restricted Stock Units, Tax Withholding, Rule 10b5-1(c)